Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Metformin in Prevention of Glucocorticoid-Induced Hyperglycemia in Patients Without Diabetes: A Meta-Analysis.

Endocrinology, diabetes & metabolism·2026
Same author

Myasthenia Gravis With Chronic Kidney Disease: A Diagnostic Challenge.

Clinical case reports·2026
Same author

Optimizing riociguat therapy for pulmonary hypertension: A systematic review and meta-analysis of dose variability, safety, and efficacy.

Medicine·2026
Same author

Travoprost intraocular implants: pioneering a new approach in ocular hypertension management.

Annals of medicine and surgery (2012)·2025
Same author

FDA approval of imetelstat: a new era in the treatment of lower-risk myelodysplastic syndrome.

Annals of medicine and surgery (2012)·2025
Same author

Maternal morbidity amidst the humanitarian crisis in Gaza.

Medicine, conflict, and survival·2025

Related Experiment Video

Updated: Jun 9, 2026

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

Reproxalap - A Novel Treatment Option for Allergic Conjunctivitis - A Comprehensive Narrative Review.

Sanila Mughal1, Roshanay Ejaz Awan1, Hur Abbas1

  • 1Department of Medicine Dow University of Health Sciences Karachi Pakistan.

Health Science Reports
|June 8, 2026
PubMed
Summary

Reproxalap, a novel treatment for allergic conjunctivitis, effectively reduces ocular itching and inflammation by inhibiting reactive aldehyde species (RASP). Clinical trials show promising efficacy and a favorable safety profile for this new therapeutic option.

More Related Videos

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Related Experiment Videos

Last Updated: Jun 9, 2026

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Allergic conjunctivitis affects 10-20% of the global population.
  • Current treatments have limitations in efficacy and side effects.
  • Reproxalap is a novel ophthalmic solution targeting reactive aldehyde species (RASP).

Purpose of the Study:

  • To assess the therapeutic potential and clinical efficacy of Reproxalap for allergic conjunctivitis.
  • To review the pharmacological profile and clinical trial performance of Reproxalap.
  • To evaluate Reproxalap's safety and tolerability in treating ocular inflammation and itching.

Main Methods:

  • A narrative review of phase 2 and phase 3 clinical trials.
  • Analysis of Reproxalap's pharmacological data.
  • Evaluation of efficacy based on symptom relief, particularly ocular itching and inflammation.

Main Results:

  • Reproxalap demonstrated early-onset, broad-spectrum anti-inflammatory activity via RASP inhibition.
  • Statistically significant improvement in itching scores and sustained symptom relief were observed.
  • Reproxalap exhibited a favorable safety profile with minimal adverse events.

Conclusions:

  • Reproxalap is a first-in-class RASP inhibitor with promising efficacy and safety for allergic conjunctivitis.
  • Its unique mechanism and clinical outcomes support its potential as a valuable therapeutic alternative.
  • Reproxalap may also be applicable to other inflammatory ocular conditions.